Increasing the efficiency of pharmacotherapy in comorbide patients with chronic brain ischemia on an outpatient basis

Authors:
T.L. VISILO¹, E.G. AREFIEV²

¹Federal State Budgetary Educational Institution of Higher Education “Kemerovo State Medical University” of the Ministry of Health of the Russian Federation, Kemerovo, Russia;
²State Budgetary Healthcare Institution “Kuzbass Clinical Cardiology Dispensary named after Academician L.S. Barbarash”, Kemerovo, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2023, Vol. 123, No. 3

Abstract:
Objective of the study. To study the efficacy and safety of sequential therapy with Mexidol (500 mg once a day for 14 days intravenously) and Mexidol FORTE 250 (Mexidol FORTE 250, 250 mg 3 times a day, 60 days) in patients with chronic cerebral ischemia (CCI) in an outpatient setting.

Material and methods. Fifty-six patients aged 46–74 years (mean 60.5±7.9 years) were included in this open comparative study. In all patients, the diagnosis of CCI was confirmed by clinical and neuroimaging methods. Patients in group 1 (n=28) received background therapy and Mexidol, while those in group 2 (n=28) received background therapy alone.

Results. During therapy, patients in Group 1 demonstrated statistically significant improvements in cognitive function, a reduction in the severity of depression and anxiety symptoms, and signs of asthenia. Treatment was well tolerated, with no adverse events or drug interactions.

Conclusion. Sequential therapy with Mexidol and Mexidol FORTE 250 provides relief of the main clinical manifestations of chronic myocardial infarction and is characterized by good tolerability and safety.

Key words: chronic cerebral ischemia, arterial hypertension, ethylmethylhydroxypyridine succinate, Mexidol, Mexidol FORTE 250.